---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-047743"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2026-04-27T23:59:59+00:00"
generated_at: "2026-05-15T04:08:56.646593+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Oruka Phase 2a EVERLAST-A meets primary endpoint: 63.5% PASI 100 at Week 16 in psoriasis

## Summary
- ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 vs 4.8% placebo (p<0.0001), exceeding primary endpoint.
- Secondary endpoints: PASI 90 82.5%, IGA 0 63.5%, IGA 0/1 84.1% vs 4.8% placebo.
- Safety: well-tolerated; no serious TEAEs, no discontinuations; URI 19% vs 14% placebo.
- Updated Phase 1 PK/PD data support once-yearly dosing; concentrations above effective trough for 52 weeks.
- Longer-term EVERLAST-A data (Week 28, 52-wk) expected 2H 2026; EVERLAST-B Phase 2b data expected 2027.

## SEC filing metadata
- accession: 0001213900-26-047743
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2026-04-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000121390026047743/0001213900-26-047743-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000121390026047743/ea0287782-8k_oruka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-047743
- JSON: https://secwatch.observer/filing/0001213900-26-047743.json
- Plain text: https://secwatch.observer/filing/0001213900-26-047743.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.